Literature DB >> 16155362

Expression of heregulin in human coronary atherosclerotic lesions.

Dimitrios Panutsopulos1, Dimitrios L Arvanitis, Christos Tsatsanis, Efstathios Papalambros, Fragiska Sigala, Demetrios A Spandidos.   

Abstract

BACKGROUND: Endothelial cells, monocytes/macrophages, and vascular smooth muscle cells contribute to the establishment and progression of atherosclerotic lesions by expressing growth and inflammatory factors. The aim of the present study was to determine whether heregulin (HRG) is associated with human coronary artery disease.
METHODS: Twenty-six fresh human coronary artery segments were collected at autopsy. Expression of cysteine-rich 61 (CYR61) and VEGF in response to HRG was studied in the human endothelial cell line EA.hy926, and expression of CYR61 and HRG was evaluated in activated macrophages isolated from peripheral blood of healthy donors.
RESULTS: We found that HRG was overexpressed at the protein and mRNA level in all lesions analyzed and gradually increased as the stages of the lesions progressed. Expression of HRG was observed in the intima primarily in macrophages. The same specimens were analyzed for the expression of CYR61, an angiogenetic factor regulated by HRG in breast cancer epithelial cells. CYR61 was expressed in both normal and atheromatic specimens, but its expression was significantly enhanced in macrophages of the intima. Activation of primary human macrophages results in increased expression of both HRG and CYR61. In addition, studies in endothelial cells where no endogenous HRG is present showed that HRG induces expression of CYR61 and secretion of VEGF.
CONCLUSIONS: HRG may, therefore, play an important role in the development of coronary artery disease and the expansion of the atherosclerotic plaque and may locally regulate the expression of the angiogenetic factor CYR61.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155362     DOI: 10.1159/000088100

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  10 in total

Review 1.  Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis.

Authors:  Nadia Hedhli; Kerry Strong Russell
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

Review 2.  Neuregulin signaling and heart failure.

Authors:  Zhenggang Jiang; Mingdong Zhou
Journal:  Curr Heart Fail Rep       Date:  2010-03

3.  High ErbB3 activating activity in human blood is not due to circulating neuregulin-1 beta.

Authors:  Emmanuel Boateng; Joanne T deKay; Sarah M Peterson; Jacob Boles; Nathan Pinnette; Mary W Sorcher; Michael P Robich; Douglas B Sawyer; Sergey Ryzhov
Journal:  Life Sci       Date:  2020-04-03       Impact factor: 5.037

4.  Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia.

Authors:  Carrie Anna Geisberg; Guisong Wang; Radwan N Safa; Holly M Smith; Brent Anderson; Xu-Yang Peng; Brian Veerkamp; David X Zhao; Dana Blakemore; Chang Yu; Douglas B Sawyer
Journal:  Coron Artery Dis       Date:  2011-12       Impact factor: 1.439

5.  Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit.

Authors:  Shahida Shafi; David Lamb; Helmout Modjtahedi; Gordon Ferns
Journal:  Int J Exp Pathol       Date:  2009-12-11       Impact factor: 1.925

Review 6.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 7.  Neuregulin in cardiovascular development and disease.

Authors:  Oghenerukevwe Odiete; Michael F Hill; Douglas B Sawyer
Journal:  Circ Res       Date:  2012-10-26       Impact factor: 17.367

8.  Does neuregulin-1 play a role in Type A behavior? The cardiovascular risk in young Finns study.

Authors:  Helena M Service; Mirka Hintsanen; Taina Hintsa; Terho Lehtimäki; Olli T Raitakari; Jorma S Viikari; Liisa Keltikangas-Järvinen
Journal:  Behav Brain Funct       Date:  2008-09-17       Impact factor: 3.759

9.  HRG-β1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells.

Authors:  Jinkyoung Kim; Hoiseon Jeong; Youngseok Lee; Chungyeul Kim; Hankyeom Kim; Aeree Kim
Journal:  BMC Cancer       Date:  2013-08-12       Impact factor: 4.430

Review 10.  Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.

Authors:  Andrew Geissler; Sergey Ryzhov; Douglas B Sawyer
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.